Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday

Core Insights - BioMarin Pharmaceutical reported strong third-quarter earnings, leading to a nearly 2% increase in stock price the following day, outperforming the S&P 500 index which rose by 1.2% [1] Financial Performance - The company's revenue for the quarter was $776 million, reflecting a 4% year-over-year increase [2] - Non-GAAP net income fell sharply by 88% to $22 million, equating to $0.12 per share, which was better than analysts' expectations of a non-GAAP net loss of $0.12 per share [2][3] - BioMarin missed revenue expectations, with analysts predicting over $782 million [3] Strategic Decisions - BioMarin announced plans to consider divesting its product Roctavian, which treats severe hemophilia A, aligning with its portfolio strategy to ensure continued patient access to the drug [4] Guidance Revision - The company raised its full-year 2025 revenue guidance to a range of $3.15 billion to $3.2 billion, up from a previous estimate of less than $3.13 billion to $3.2 billion [5] - Adjusted per-share net income guidance was reduced to $3.50 to $3.60, down from a prior forecast of $4.40 to $4.55 [5]